The deubiquitinase YOD1 suppresses tumor progression by stabilizing ZNF24 in clear cell renal carcinoma

被引：0

作者：

Ji Liu ^{[1
]}

Ying Lu ^{[2
]}

Runye Zhu ^{[3
]}

Ping Xi ^{[1
]}

Zhihao Yang ^{[2
]}

Zhipeng Zhang ^{[4
]}

Yunbing Xiong ^{[1
]}

Yifu Liu ^{[2
]}

Qiqi Zhu ^{[1
]}

Ting Sun ^{[2
]}

Wenjie Xie ^{[1
]}

Binbin Gong ^{[2
]}

机构：

[1] Department of Urology, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Jiangxi, Nanchang

[2] Jiangxi Provincial Key Laboratory of Urinary System Diseases, Jiangxi Province, Nanchang City

[3] Department of Clinical Laboratory, The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, Jiangxi, Nanchang

[4] Department of Thoracic Surgery, XinSteel Center Hospital, Xinyu

[5] The Second Affiliated Hospital, Department of Urology, Hengyang Medical School, University of South China, Hunan, Hengyang

来源：

Cell Death & Disease | / 16卷 / 1期

基金：

中国国家自然科学基金;

关键词：

D O I：

10.1038/s41419-025-07673-2

中图分类号：

学科分类号：

摘要：

Metastasis remains a significant challenge in the management of clear cell renal cell carcinoma (ccRCC), and a continued focus on its underlying mechanisms is crucial for improving patient outcomes and optimizing clinical therapies. The ovarian-tumor related protease (OTU) is involved in regulating critical cell signaling pathways, but the functions of most OTUs have yet to be explored. In this study, an unbiased RNAi screening revealed that ovarian tumor domain-containing 2 (YOD1) knockdown significantly promoted cell metastasis. YOD1 downregulation promoted ccRCC growth and metastasis both in vitro and in vivo. Notably, YOD1 knockdown stimulated the growth of organoids derived from ccRCC patients. Further investigation revealed that YOD1 directly interacted with and stabilized Zinc finger protein 24 (ZNF24) expression by deubiquitination in a manner dependent on its catalytic activity. YOD1 inhibition attenuated ZNF24 transcriptional repression of vascular endothelial growth factor A (VEGFA), thereby promoting VEGFA gene expression. Furthermore, ZNF24 was identified as a key mediator of YOD1 function. The expression of YOD1 and ZNF24 was significantly downregulated in tumor tissues, with a strong correlation between them. Importantly, reduced YOD1 and ZNF24 levels were strongly associated with poor clinical outcomes in ccRCC patients. Our results reveal the mechanism by which YOD1 regulates VEGFA transcription and suppresses tumorigenesis by deubiquitinating ZNF24, providing a therapeutic target in ccRCC. © The Author(s) 2025.

引用

共 54 条

[1]

Linehan W.M., Ricketts C.J., The Cancer Genome Atlas of renal cell carcinoma: findings and clinical implications, Nat Rev Urol, 16, pp. 539-552, (2019)

[2]

Siegel R.L., Miller K.D., Wagle N.S., Jemal A., Cancer statistics, 2023, CA Cancer J Clin, 73, pp. 17-48, (2023)

[3]

Gill I.S., Cacciamani G.E., Duddalwar V., Thangathurai D., Cunningham M., Renal cancer with extensive level IV intracardiac tumour thrombus removed by robot, Lancet, 396, (2020)

[4]

Uhlig A., Bergmann L., Bogemann M., Fischer T., Goebell P.J., Leitsmann M., Et al., Sunitinib for metastatic renal cell carcinoma: real-world data from the STAR-TOR registry and detailed literature review, Urol Int, 108, pp. 198-210, (2024)

[5]

Jiang A., Li J., He Z., Liu Y., Qiao K., Fang Y., Et al., Renal cancer: signaling pathways and advances in targeted therapies, MedComm (2020), 5, (2024)

[6]

Ravaud A., Motzer R.J., Pandha H.S., George D.J., Pantuck A.J., Patel A., Et al., Adjuvant sunitinib in high-risk renal-cell carcinoma after nephrectomy, N Engl J Med, 375, pp. 2246-2254, (2016)

[7]

Cohen P., Tcherpakov M., Will the ubiquitin system furnish as many drug targets as protein kinases?, Cell, 143, pp. 686-693, (2010)

[8]

Shen J., Fu B., Li Y., Wu Y., Sang H., Zhang H., Et al., E3 Ubiquitin ligase-mediated regulation of osteoblast differentiation and bone formation, Front Cell Dev Biol, 9, (2021)

[9]

Schraml P., Struckmann K., Hatz F., Sonnet S., Kully C., Gasser T., Et al., VHL mutations and their correlation with tumour cell proliferation, microvessel density, and patient prognosis in clear cell renal cell carcinoma, J Pathol, 196, pp. 186-193, (2002)

[10]

Rose T.L., Kim W.Y., Renal cell carcinoma: a review, Jama, 332, pp. 1001-1010, (2024)

← 1 2 3 4 5 6 →